Perioperative tight glycemic control using artificial pancreas decreases infectious complications via suppression of inflammatory cytokines in patients who underwent pancreaticoduodenectomy: A prospective, non-randomized clinical trial
We sought to investigate the efficacy of perioperative tight glycemic control (TGC) in reducing of postoperative infectious complications (POICs) and study its impact on early inflammatory mediators in patients who underwent pancreaticoduodenectomy. In this non-randomized trial, the artificial pancr...
Gespeichert in:
| Veröffentlicht in: | The American journal of surgery 2020-08, Vol.220 (2), p.365-371 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 371 |
|---|---|
| container_issue | 2 |
| container_start_page | 365 |
| container_title | The American journal of surgery |
| container_volume | 220 |
| creator | Akabori, Hiroya Tani, Masaji Kitamura, Naomi Maehira, Hiromitsu Imashuku, Yasuhiko Tsujita, Yasuyuki Shimizu, Tomoharu Kitagawa, Hirotoshi Eguchi, Yutaka |
| description | We sought to investigate the efficacy of perioperative tight glycemic control (TGC) in reducing of postoperative infectious complications (POICs) and study its impact on early inflammatory mediators in patients who underwent pancreaticoduodenectomy.
In this non-randomized trial, the artificial pancreas (AP) group received TGC (target glucose range of 80–110 mg/dL; n = 14), while the control group received conventional glycemic control (range of 80–180 mg/dL; n = 15). The primary endpoint was POICs.
The AP group had a markedly decreased POIC rate (28.6% vs. 73.3%; P = 0.027), mean glycemic variability (13.5 ± 3.5% vs. 16.4 ± 5.9%; P = 0.038), and plasma interleukin-6 level (26.3 ± 33.8 vs 98.3 ± 89.1 pg/ml; P = 0.036) compared to the control group, but insulin dosage (27.0 ± 13.4 vs. 10.2 ± 16.2 U; P = 0.002) and the adiponectin ratio (i.e., postoperative/preoperative adiponectin; 0.8 ± 0.2 vs. 0.6 ± 0.3; P = 0.021) were markedly higher in the AP group.
Among patients undergoing PD with impaired glucose tolerance, AP facilitated strict glycemic control and resulted in a reduction of anti-inflammatory mediators and POICs.
Perioperative hyperglycemia increases postoperative infectious complications; however, tight glycemic control using artificial pancreas can reduce them via a dual effect. Artificial pancreas facilitates strict and safe glycemic control while reducing anti-inflammatory mediators, including adiponectin, following pancreaticoduodenectomy.
•Artificial pancreas facilitates strict glycemic control after pancreatic surgery.•Tight glycemic control reduces infectious complications in patients with diabetes.•Postoperative glycemic variability is important in perioperative glycemic control.•Adipose tissue inflammation is associated with postoperative infectious complication. . |
| doi_str_mv | 10.1016/j.amjsurg.2019.12.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2336997808</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961019315594</els_id><sourcerecordid>2425700606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-8e6bc645a803b6c317f690ede9e358be29f849e9b071c6669dfd46250e7d2c213</originalsourceid><addsrcrecordid>eNqFUsGO0zAQjRBIlIVPQLLEhQMptpM6Nhe0Wu0C0kpwgLPl2pPulMQOttNV-GV-Yt12uXDhNJrRm_fePE1VvWZ0zSgT7_drM-7THHdrTplaM76mVD6pVkx2qmZSNk-rFaWU10ow-rx6kdK-tIy1zar68w0ihgmiyXgAknF3l8luWCyMaIkNPscwkDmh3xETM_Zo0QxkMt5GMIk4OFVIBH0PNmOYU1kbpwFtoQw-kQMakuZpipBSGZDQH7GDGUeTQ1yIXXL4if5EUYgzgs-J3N8FMnsH8b60f_Uy2uDm4MAXqTAuH8glmWJI01H5AO-ID76Oxrsw4m9wxA7oi4-B5Fhcv6ye9WZI8OqxXlQ_bq6_X32ub79--nJ1eVvbVtJcSxBbK9qNkbTZCtuwrheKggMFzUZugatetgrUlnbMCiGU610r-IZC57jlrLmo3p55i7VfM6SsR0wWhsF4KPFo3jRCqU5SWaBv_oHuwxx9cad5yzcdpYKKgtqcUbbcmiL0eoo4mrhoRvXxBfReP76APr6AZlzTE_vH8x6Uaw8IUSdb0rXgMJbEtAv4H4YH847GQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425700606</pqid></control><display><type>article</type><title>Perioperative tight glycemic control using artificial pancreas decreases infectious complications via suppression of inflammatory cytokines in patients who underwent pancreaticoduodenectomy: A prospective, non-randomized clinical trial</title><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Akabori, Hiroya ; Tani, Masaji ; Kitamura, Naomi ; Maehira, Hiromitsu ; Imashuku, Yasuhiko ; Tsujita, Yasuyuki ; Shimizu, Tomoharu ; Kitagawa, Hirotoshi ; Eguchi, Yutaka</creator><creatorcontrib>Akabori, Hiroya ; Tani, Masaji ; Kitamura, Naomi ; Maehira, Hiromitsu ; Imashuku, Yasuhiko ; Tsujita, Yasuyuki ; Shimizu, Tomoharu ; Kitagawa, Hirotoshi ; Eguchi, Yutaka</creatorcontrib><description>We sought to investigate the efficacy of perioperative tight glycemic control (TGC) in reducing of postoperative infectious complications (POICs) and study its impact on early inflammatory mediators in patients who underwent pancreaticoduodenectomy.
In this non-randomized trial, the artificial pancreas (AP) group received TGC (target glucose range of 80–110 mg/dL; n = 14), while the control group received conventional glycemic control (range of 80–180 mg/dL; n = 15). The primary endpoint was POICs.
The AP group had a markedly decreased POIC rate (28.6% vs. 73.3%; P = 0.027), mean glycemic variability (13.5 ± 3.5% vs. 16.4 ± 5.9%; P = 0.038), and plasma interleukin-6 level (26.3 ± 33.8 vs 98.3 ± 89.1 pg/ml; P = 0.036) compared to the control group, but insulin dosage (27.0 ± 13.4 vs. 10.2 ± 16.2 U; P = 0.002) and the adiponectin ratio (i.e., postoperative/preoperative adiponectin; 0.8 ± 0.2 vs. 0.6 ± 0.3; P = 0.021) were markedly higher in the AP group.
Among patients undergoing PD with impaired glucose tolerance, AP facilitated strict glycemic control and resulted in a reduction of anti-inflammatory mediators and POICs.
Perioperative hyperglycemia increases postoperative infectious complications; however, tight glycemic control using artificial pancreas can reduce them via a dual effect. Artificial pancreas facilitates strict and safe glycemic control while reducing anti-inflammatory mediators, including adiponectin, following pancreaticoduodenectomy.
•Artificial pancreas facilitates strict glycemic control after pancreatic surgery.•Tight glycemic control reduces infectious complications in patients with diabetes.•Postoperative glycemic variability is important in perioperative glycemic control.•Adipose tissue inflammation is associated with postoperative infectious complication. .</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2019.12.008</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Abdominal surgery ; Adiponectin ; Artificial pancreas ; Clinical trials ; Complications ; Cytokines ; Diabetes ; Glucose ; Glucose tolerance ; Hyperglycemia ; Hypoglycemia ; Infections ; Inflammation ; Insulin ; Insulin resistance ; Interleukin 6 ; Interleukins ; Laboratories ; Metabolism ; Pancreas ; Pancreaticoduodenectomy ; Patients ; Plasma ; Postoperative period ; Surgeons ; Tight glycemic control</subject><ispartof>The American journal of surgery, 2020-08, Vol.220 (2), p.365-371</ispartof><rights>2019 Elsevier Inc.</rights><rights>2019. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-8e6bc645a803b6c317f690ede9e358be29f849e9b071c6669dfd46250e7d2c213</citedby><cites>FETCH-LOGICAL-c480t-8e6bc645a803b6c317f690ede9e358be29f849e9b071c6669dfd46250e7d2c213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2425700606?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997,64387,64389,64391,72471</link.rule.ids></links><search><creatorcontrib>Akabori, Hiroya</creatorcontrib><creatorcontrib>Tani, Masaji</creatorcontrib><creatorcontrib>Kitamura, Naomi</creatorcontrib><creatorcontrib>Maehira, Hiromitsu</creatorcontrib><creatorcontrib>Imashuku, Yasuhiko</creatorcontrib><creatorcontrib>Tsujita, Yasuyuki</creatorcontrib><creatorcontrib>Shimizu, Tomoharu</creatorcontrib><creatorcontrib>Kitagawa, Hirotoshi</creatorcontrib><creatorcontrib>Eguchi, Yutaka</creatorcontrib><title>Perioperative tight glycemic control using artificial pancreas decreases infectious complications via suppression of inflammatory cytokines in patients who underwent pancreaticoduodenectomy: A prospective, non-randomized clinical trial</title><title>The American journal of surgery</title><description>We sought to investigate the efficacy of perioperative tight glycemic control (TGC) in reducing of postoperative infectious complications (POICs) and study its impact on early inflammatory mediators in patients who underwent pancreaticoduodenectomy.
In this non-randomized trial, the artificial pancreas (AP) group received TGC (target glucose range of 80–110 mg/dL; n = 14), while the control group received conventional glycemic control (range of 80–180 mg/dL; n = 15). The primary endpoint was POICs.
The AP group had a markedly decreased POIC rate (28.6% vs. 73.3%; P = 0.027), mean glycemic variability (13.5 ± 3.5% vs. 16.4 ± 5.9%; P = 0.038), and plasma interleukin-6 level (26.3 ± 33.8 vs 98.3 ± 89.1 pg/ml; P = 0.036) compared to the control group, but insulin dosage (27.0 ± 13.4 vs. 10.2 ± 16.2 U; P = 0.002) and the adiponectin ratio (i.e., postoperative/preoperative adiponectin; 0.8 ± 0.2 vs. 0.6 ± 0.3; P = 0.021) were markedly higher in the AP group.
Among patients undergoing PD with impaired glucose tolerance, AP facilitated strict glycemic control and resulted in a reduction of anti-inflammatory mediators and POICs.
Perioperative hyperglycemia increases postoperative infectious complications; however, tight glycemic control using artificial pancreas can reduce them via a dual effect. Artificial pancreas facilitates strict and safe glycemic control while reducing anti-inflammatory mediators, including adiponectin, following pancreaticoduodenectomy.
•Artificial pancreas facilitates strict glycemic control after pancreatic surgery.•Tight glycemic control reduces infectious complications in patients with diabetes.•Postoperative glycemic variability is important in perioperative glycemic control.•Adipose tissue inflammation is associated with postoperative infectious complication. .</description><subject>Abdominal surgery</subject><subject>Adiponectin</subject><subject>Artificial pancreas</subject><subject>Clinical trials</subject><subject>Complications</subject><subject>Cytokines</subject><subject>Diabetes</subject><subject>Glucose</subject><subject>Glucose tolerance</subject><subject>Hyperglycemia</subject><subject>Hypoglycemia</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Interleukin 6</subject><subject>Interleukins</subject><subject>Laboratories</subject><subject>Metabolism</subject><subject>Pancreas</subject><subject>Pancreaticoduodenectomy</subject><subject>Patients</subject><subject>Plasma</subject><subject>Postoperative period</subject><subject>Surgeons</subject><subject>Tight glycemic control</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFUsGO0zAQjRBIlIVPQLLEhQMptpM6Nhe0Wu0C0kpwgLPl2pPulMQOttNV-GV-Yt12uXDhNJrRm_fePE1VvWZ0zSgT7_drM-7THHdrTplaM76mVD6pVkx2qmZSNk-rFaWU10ow-rx6kdK-tIy1zar68w0ihgmiyXgAknF3l8luWCyMaIkNPscwkDmh3xETM_Zo0QxkMt5GMIk4OFVIBH0PNmOYU1kbpwFtoQw-kQMakuZpipBSGZDQH7GDGUeTQ1yIXXL4if5EUYgzgs-J3N8FMnsH8b60f_Uy2uDm4MAXqTAuH8glmWJI01H5AO-ID76Oxrsw4m9wxA7oi4-B5Fhcv6ye9WZI8OqxXlQ_bq6_X32ub79--nJ1eVvbVtJcSxBbK9qNkbTZCtuwrheKggMFzUZugatetgrUlnbMCiGU610r-IZC57jlrLmo3p55i7VfM6SsR0wWhsF4KPFo3jRCqU5SWaBv_oHuwxx9cad5yzcdpYKKgtqcUbbcmiL0eoo4mrhoRvXxBfReP76APr6AZlzTE_vH8x6Uaw8IUSdb0rXgMJbEtAv4H4YH847GQQ</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Akabori, Hiroya</creator><creator>Tani, Masaji</creator><creator>Kitamura, Naomi</creator><creator>Maehira, Hiromitsu</creator><creator>Imashuku, Yasuhiko</creator><creator>Tsujita, Yasuyuki</creator><creator>Shimizu, Tomoharu</creator><creator>Kitagawa, Hirotoshi</creator><creator>Eguchi, Yutaka</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20200801</creationdate><title>Perioperative tight glycemic control using artificial pancreas decreases infectious complications via suppression of inflammatory cytokines in patients who underwent pancreaticoduodenectomy: A prospective, non-randomized clinical trial</title><author>Akabori, Hiroya ; Tani, Masaji ; Kitamura, Naomi ; Maehira, Hiromitsu ; Imashuku, Yasuhiko ; Tsujita, Yasuyuki ; Shimizu, Tomoharu ; Kitagawa, Hirotoshi ; Eguchi, Yutaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-8e6bc645a803b6c317f690ede9e358be29f849e9b071c6669dfd46250e7d2c213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Abdominal surgery</topic><topic>Adiponectin</topic><topic>Artificial pancreas</topic><topic>Clinical trials</topic><topic>Complications</topic><topic>Cytokines</topic><topic>Diabetes</topic><topic>Glucose</topic><topic>Glucose tolerance</topic><topic>Hyperglycemia</topic><topic>Hypoglycemia</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Interleukin 6</topic><topic>Interleukins</topic><topic>Laboratories</topic><topic>Metabolism</topic><topic>Pancreas</topic><topic>Pancreaticoduodenectomy</topic><topic>Patients</topic><topic>Plasma</topic><topic>Postoperative period</topic><topic>Surgeons</topic><topic>Tight glycemic control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akabori, Hiroya</creatorcontrib><creatorcontrib>Tani, Masaji</creatorcontrib><creatorcontrib>Kitamura, Naomi</creatorcontrib><creatorcontrib>Maehira, Hiromitsu</creatorcontrib><creatorcontrib>Imashuku, Yasuhiko</creatorcontrib><creatorcontrib>Tsujita, Yasuyuki</creatorcontrib><creatorcontrib>Shimizu, Tomoharu</creatorcontrib><creatorcontrib>Kitagawa, Hirotoshi</creatorcontrib><creatorcontrib>Eguchi, Yutaka</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akabori, Hiroya</au><au>Tani, Masaji</au><au>Kitamura, Naomi</au><au>Maehira, Hiromitsu</au><au>Imashuku, Yasuhiko</au><au>Tsujita, Yasuyuki</au><au>Shimizu, Tomoharu</au><au>Kitagawa, Hirotoshi</au><au>Eguchi, Yutaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perioperative tight glycemic control using artificial pancreas decreases infectious complications via suppression of inflammatory cytokines in patients who underwent pancreaticoduodenectomy: A prospective, non-randomized clinical trial</atitle><jtitle>The American journal of surgery</jtitle><date>2020-08-01</date><risdate>2020</risdate><volume>220</volume><issue>2</issue><spage>365</spage><epage>371</epage><pages>365-371</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><abstract>We sought to investigate the efficacy of perioperative tight glycemic control (TGC) in reducing of postoperative infectious complications (POICs) and study its impact on early inflammatory mediators in patients who underwent pancreaticoduodenectomy.
In this non-randomized trial, the artificial pancreas (AP) group received TGC (target glucose range of 80–110 mg/dL; n = 14), while the control group received conventional glycemic control (range of 80–180 mg/dL; n = 15). The primary endpoint was POICs.
The AP group had a markedly decreased POIC rate (28.6% vs. 73.3%; P = 0.027), mean glycemic variability (13.5 ± 3.5% vs. 16.4 ± 5.9%; P = 0.038), and plasma interleukin-6 level (26.3 ± 33.8 vs 98.3 ± 89.1 pg/ml; P = 0.036) compared to the control group, but insulin dosage (27.0 ± 13.4 vs. 10.2 ± 16.2 U; P = 0.002) and the adiponectin ratio (i.e., postoperative/preoperative adiponectin; 0.8 ± 0.2 vs. 0.6 ± 0.3; P = 0.021) were markedly higher in the AP group.
Among patients undergoing PD with impaired glucose tolerance, AP facilitated strict glycemic control and resulted in a reduction of anti-inflammatory mediators and POICs.
Perioperative hyperglycemia increases postoperative infectious complications; however, tight glycemic control using artificial pancreas can reduce them via a dual effect. Artificial pancreas facilitates strict and safe glycemic control while reducing anti-inflammatory mediators, including adiponectin, following pancreaticoduodenectomy.
•Artificial pancreas facilitates strict glycemic control after pancreatic surgery.•Tight glycemic control reduces infectious complications in patients with diabetes.•Postoperative glycemic variability is important in perioperative glycemic control.•Adipose tissue inflammation is associated with postoperative infectious complication. .</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/j.amjsurg.2019.12.008</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9610 |
| ispartof | The American journal of surgery, 2020-08, Vol.220 (2), p.365-371 |
| issn | 0002-9610 1879-1883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2336997808 |
| source | Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Abdominal surgery Adiponectin Artificial pancreas Clinical trials Complications Cytokines Diabetes Glucose Glucose tolerance Hyperglycemia Hypoglycemia Infections Inflammation Insulin Insulin resistance Interleukin 6 Interleukins Laboratories Metabolism Pancreas Pancreaticoduodenectomy Patients Plasma Postoperative period Surgeons Tight glycemic control |
| title | Perioperative tight glycemic control using artificial pancreas decreases infectious complications via suppression of inflammatory cytokines in patients who underwent pancreaticoduodenectomy: A prospective, non-randomized clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T09%3A38%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perioperative%20tight%20glycemic%20control%20using%20artificial%20pancreas%20decreases%20infectious%20complications%20via%20suppression%20of%20inflammatory%20cytokines%20in%20patients%20who%20underwent%20pancreaticoduodenectomy:%20A%20prospective,%20non-randomized%20clinical%20trial&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Akabori,%20Hiroya&rft.date=2020-08-01&rft.volume=220&rft.issue=2&rft.spage=365&rft.epage=371&rft.pages=365-371&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/j.amjsurg.2019.12.008&rft_dat=%3Cproquest_cross%3E2425700606%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425700606&rft_id=info:pmid/&rft_els_id=S0002961019315594&rfr_iscdi=true |